Progyny, Inc. (PGNY) Stock
Progyny stock price chart
PGNY stock quote & key statistics
PGNY stock performance
Progyny shares are up 34.9% over the past year and trade near the top of their 52-week range of $16.10–$37.16. The company has a market cap of $2.66B and a P/E ratio of 33.6.
PGNY financial performance
In fiscal 2025, Progyny's revenue was $1.29B, an increase of 10.4% from $1.17B the year before. Net income was $58.5M, up 7.7%, and earnings per share were $1.26.
PGNY analyst forecast
According to 12 analysts, the average rating for PGNY stock is "Strong Buy." The 12-month price target is $34.42, which is 4.9% below the latest price.
Progyny annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $1.29B | $58.5M | $1.26 |
| FY2024 | $1.17B | $54.3M | $1.64 |
| FY2023 | $1.09B | $62.0M | $0.62 |
| FY2022 | $786.9M | $30.4M | $0.30 |
| FY2021 | $500.6M | $65.8M | $0.66 |
Fiscal year ending December 31. Source: company filings via EODHD.
About Progyny, Inc.
Progyny, Inc., headquartered in New York, New York, is a leading benefits management company specializing in providing comprehensive fertility and family building solutions for employers across the United States. Established in 2008 and formerly known as Auxogyn, Inc., Progyny focuses on delivering tailored benefits plan designs that cater specifically to fertility needs.
Progyny's fertility benefits solution encompasses personalized member support services delivered in a concierge-style approach, ensuring individuals receive compassionate guidance throughout their fertility journey. The company also offers access to a carefully curated network of fertility specialists renowned for their expertise and success rates in reproductive medicine.
In addition to its core fertility benefits, Progyny provides Progyny Rx, an integrated pharmacy benefits solution that facilitates convenient access to medications required during fertility treatments. This comprehensive approach aims to streamline the process and reduce barriers for individuals pursuing assisted reproductive technologies.
Progyny further supports family building through surrogacy and adoption reimbursement programs tailored for employers, reinforcing its commitment to comprehensive family-building benefits. With a robust foundation in supporting fertility care and reproductive health, Progyny continues to innovate and empower individuals and families nationwide.
Progyny stock FAQ
What is the Progyny stock ticker symbol?
Progyny, Inc. trades on the NASDAQ under the ticker symbol PGNY.
What sector and industry is Progyny in?
Progyny, Inc. is classified in the Healthcare sector, Healthcare Plans industry.
How many employees does Progyny have?
Progyny, Inc. has about 835 full-time employees.
What were Progyny's revenue and earnings last fiscal year?
Progyny reported revenue of $1.29B and net income of $58.5M in fiscal 2025, with earnings per share of $1.26. Revenue grew 10.4% from the prior year.
Is Progyny in the S&P SmallCap 600?
Yes. Progyny, Inc. (PGNY) is a component of the S&P SmallCap 600, the benchmark index of profitable U.S. small-cap stocks.
Is Progyny in the Russell 2000?
Yes. Progyny, Inc. (PGNY) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.
When did Progyny go public?
Progyny stock began trading on October 25, 2019.
S&P SmallCap 600 Healthcare stocks
All S&P SmallCap 600 →- ACHCAcadia Healthcare
- ALHCAlignment Healthcare
- ALKSAlkermes
- AMRXAmneal Pharmaceuticals
- ARQTArcutis Biotherapeutics
- ATRCAtriCure
- CONConcentra Group Holdings Parent
- GKOSGlaukos
- ICUIICU Medical
- INDVIndivior
- ITGRInteger
- LFSTLifeStance Health
- LGNDLigand Pharmaceuticals
- MMSIMerit Medical Systems
- NHCNational HealthCare
- OGNOrganon
- PRVAPrivia Health
- PTCTPTC Therapeutics
- PTGXProtagonist Therapeutics
- RDNTRadNet
- TFXTeleflex
- TGTXTG Therapeutics
- VCYTVeracyte
- WAYWaystar